News

Life sciences

EffRx Pharamceuticals and Lupin cooperate in South East Asia

14. February 2024

EffRx Pharmaceuticals from the canton of Schwyz and Lupin have signed an agreement for the joint commercialization of an osteoporosis medication. The agreement focuses on introducing the product to Vietnam and the Philippines.

Oase Group works with Dividat

13. February 2024

The Oase Group, which specializes in elderly care, is joining forces with the Schwyz-based medtech company Dividat. Going forward, Dividat's physical training concepts will be implemented in all Oase locations, making use of the corresponding

Octapharma obtains positive results in study on prophylaxis for patients with VWD

24. January 2024

A large-scale study has shown that an Octapharma drug reduces the annualized bleeding rate in von Willebrand disease (VWD) by 84 per cent. Following these results, this prophylaxis has recently been indicated for use in the U.S.

Spiden makes a breakthrough in non-invasive glucose measurements

16. January 2024

Spiden has made significant progress in the area of non-invasive glucose measurements. The company hopes to develop a wearable device on the basis of its new technical solution. Alongside the scientific success, Spiden has also secured financing of

Zynnon hits milestone in the diagnosis of respiratory infections

20. December 2023

Zynnon has reached a milestone with its technology for diagnosing viral respiratory infections. Following successful studies in hospitals, the Schwyz-based company has started producing prototypes. Further clinical trials will now follow.

Half a million people now use Oviva

08. December 2023

The digital health company Oviva supports more than 500,000 patients across Europe in managing conditions such as obesity and diabetes. With this therapy support, important progress has been achieved in the treatment of these common diseases.

Octapharma’s haemophilia prophylaxis performs well in comparison

09. November 2023

Nuwiq, for the personalized prophylaxis of bleeding in haemophilia A has shown significantly better results in an indirect comparison with other treatments. However, the weekly dose is higher for the drug developed by Octapharma from the canton of

Memo Therapeutics raises 25 million francs in Series C financing

02. November 2023

Memo Therapeutics has raised 25 million Swiss francs to complete the Phase II clinical trials of AntiBKV for kidney infections in transplantation. The Series C financing was led by Pureos Bioventures.

MediCrops agrees takeover of Swiss Alpinopharma

02. October 2023

The international HealthTech firm MediCrops Holding AG from the canton of Schwyz has struck a deal to acquire Swiss Alpinopharma. The Berlin-based firm has already launched cannabis-based medication on the German market and is the owner of the

Zynnon improves diagnosis of respiratory infections in hospitals

12. September 2023

Zynnon, a life sciences firm based in the canton of Schwyz, has developed a model with the capacity to accurately diagnose and predict viral respiratory infections. This has now been verified in a study. This development should make hospital

Ticino and Valais lead the way in terms of weight loss

22. August 2023

Oviva, which provides personalized nutrition consulting supported by an app, has analyzed anonymous data and discovered that people in the cantons of Ticino and Valais lost the most weight. BMI scores are highest in the canton of Schaffhausen, while

Octapharma receives approval to distribute drug in the USA

31. July 2023

Octapharma USA has received approval in the USA for its drug Balfaxar, which is marketed as Octaplex in Europe and Canada. Before surgery, the drug helps to rapidly restore blood clotting after this may have been suppressed following a heart attack.